12 completed, 4 recruiting, 1 terminated, 1 withdrawn. 18 Phase 2, 2 Phase 1, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 18 | Completed 12, Recruiting 4, Terminated 1, Withdrawn 1 |
| Phase 1 | 2 | Completed 2 |
| Phase 3 | 2 | Completed 1, Withdrawn 1 |
Follow testosterone enanthate: new trials by email Literature Review of testosterone enanthate trials Research Report on testosterone enanthate
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Working Out M0 Bipolar Androgen Therapy Testosterone Enanthate - Prostate Cancer | Phase 2 | Recruiting | Australian and New Zealand Urogenital and Prostate Cancer Trials Group | 69 | 2024-08-14 | 2026-04-24 |
| Cycled Testosterone Administration During Pulmonary Rehabilitation in Early Stage COPD Testosterone Enanthate, Placebo - COPD | Phase 2 / Phase 3 | Withdrawn | The University of Texas Medical Branch, Galveston | 2021-12-01 | 2022-02-02 | |
| Locomotor Training With Testosterone to Promote Bone and Muscle Health After Spinal Cord Injury Testosterone Enanthate, Locomotor Training - Spinal Cord Injury, Spinal Cord Injuries | Phase 2 | Recruiting | North Florida Foundation for Research and Education | 21 | 2021-01-31 | 2025-05-06 |
| Sequential Testosterone and Enzalutamide Prevents Unfavorable Progression Testosterone cypionate, Enzalutamide, Testosterone enanthate - Castration Resistant Metastatic Prostate Cancer | Phase 2 | Recruiting | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 150 | 2020-08-19 | 2026-07-17 |
| Testosterone and Olaparib in Treating Patients With Castration-Resistant Prostate Cancer Laboratory Biomarker Analysis, Olaparib, Quality-of-Life Assessment - Castration-Resistant Prostate Carcinoma, Prostate Adenocarcinoma | Phase 2 | Completed | University of Washington | 36 | 2018-08-29 | 2025-09-29 |
| Bipolar Androgen Therapy + Carboplatin in mCRPC Testosterone Enanthate 100 MG/ML Injectable Solution, Testosterone Enanthate 100 MG/ML Injectable Solution / Carboplatin AUC 5 - Castration-resistant Prostate Cancer, Homologous Recombination Deficiency | Phase 2 | Recruiting | St Vincent's Hospital, Sydney | 30 | 2018-07-30 | 2026-04-23 |
| Testosterone Plus Finasteride Treatment After Spinal Cord Injury Testosterone Enanthate, Finasteride, Placebo injection - Spinal Cord Injury, Spinal Cord Injuries | Phase 2 | Terminated | VA Office of Research and Development | 33 | 2017-04-27 | 2023-09-29 |
| Safety of Subcutaneous Testosterone Enanthate in Adult Male Hypogonadism Testosterone enanthate auto-injector - Hypogonadism | Phase 2 | Completed | Antares Pharma Inc. | 66 | 2016-06-01 | 2018-03-22 |
| Testosterone Revival Abolishes Negative Symptoms, Fosters Objective Response and Modulates Enzalutamide Resistance Testosterone cypionate, Enzalutamide, Testosterone Enanthate - Castration Resistant Metastatic Prostate Cancer | Phase 2 | Completed | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 222 | 2015-01-01 | 2020-11-06 |
| RE-sensitizing With Supraphysiologic Testosterone to Overcome REsistance (The RESTORE Study) Testosterone cypionate, Testosterone Enanthate, Abiraterone acetate - Prostate Cancer | Phase 2 | Completed | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 112 | 2014-08-25 | 2022-06-27 |
| Pharmacokinetic Study of Testosterone Enanthate QuickShot™ - 50 mg Treatment B, QuickShot™ - 100 mg Treatment A, Delatestryl 200 mg IM Treatment C - Hypogonadism | Phase 1 / Phase 2 | Completed | Antares Pharma Inc. | 39 | 2013-09-01 | 2018-01-11 |
| Pharmacokinetic Study of Oral Testosterone (T) Ester Formulations in Hypogonadal Men Oral testosterone undecanoate (TU) (300 mg T equivalents/dose), Oral testosterone undecanoate (TU) combined with testosterone enanthate (TE) (400 mg T equivalents/dose), Oral testosterone undecanoate (TU) (200 mg T equivalents/dose with and without food) - Hypogonadism | Phase 2 | Completed | Clarus Therapeutics, Inc. | 29 | 2008-06-01 | 2021-06-25 |
| Pilot Pharmacokinetic Study of Oral Testosterone Ester Formulations in Hypogonadal Men Testosterone undecanoate, Testosterone enanthate - Hypogonadism | Phase 2 | Completed | Clarus Therapeutics, Inc. | 12 | 2007-11-01 | 2018-11-01 |
| 5-Alpha Reductase and Anabolic Effects of Testosterone Testosterone Enanthate, Finasteride, Placebo - Male Hypogonadism, Muscle Atrophy | Phase 2 | Completed | VA Office of Research and Development | 60 | 2007-01-01 | 2018-10-11 |
| Oral Androgens in Man-4: (Short Title: Oral T-4) Testosterone Enanthate, Dutasteride, placebo sesame oil - Contraception | Phase 1 / Phase 2 | Completed | University of Washington | 20 | 2006-11-01 | 2008-09-22 |
| Testosterone and Physical Function in HIV+ Men Testosterone enanthate, Placebo - HIV Associate Weight Loss | Phase 2 | Completed | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 61 | 2003-05-01 | 2018-03-09 |
| Study to Determine the Effects of Testosterone Replacement Therapy in Aging Men With Androgen Deficiency Testosterone Enanthate, Placebo - Men With Low Testosterone Levels | Phase 2 / Phase 3 | Completed | Leonard S. Marks, M.D. | 44 | 2003-04-01 | 2021-04-28 |
| A Study of Megestrol Acetate Alone or in Combination With Testosterone Enanthate Drug in the Treatment of HIV-Associated Weight Loss Testosterone enanthate, Megestrol acetate - HIV Infections, HIV Wasting Syndrome | Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 80 | 2021-11-01 |
Hypogonadism (6) · Eunuchism (3) · Bone Resorption (2) · Central Nervous System Diseases (2) · Endocrine System Diseases (2) · Genital Diseases, Male (2) · Gonadal Disorders (2) · Nervous System Diseases (2) · Prostatic Neoplasms (2) · Spinal Cord Diseases (2) · Spinal Cord Injuries (2) · Trauma, Nervous System (2) · Wounds and Injuries (2) · AIDS-Related Complex (1) · Acquired Immunodeficiency Syndrome (1)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (3) · Antares Pharma Inc. (2) · Clarus Therapeutics, Inc. (2) · University of Washington (2) · VA Office of Research and Development (2) · Australian and New Zealand Urogenital and Prostate Cancer Trials Group (1) · Leonard S. Marks, M.D. (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (1) · North Florida Foundation for Research and Education (1) · St Vincent's Hospital, Sydney (1) · The University of Texas Medical Branch, Galveston (1)
United States (16) · Australia (2)
Samuel Denmeade, MD (3) · Anthony Joshua (1) · Anthony M Joshua, MBBS, PhD, FRACP (1) · Dana M Otzel, PhD (1) · Dana M Otzel, Phd (1) · Gary Bedel, MD (1) · Gregory Flippo, M.D. (1) · Jed Kaminetsky, MD (1) · John K Amory, MD, MPH (1) · Joshua F Yarrow, PhD (1) · Joshua F Yarrow, PhD MS BS (1) · Leonard S Marks, M.D. (1) · Michael T. Schweizer (1) · Mulligan K (1) · Randall J Urban, MD (1)
PMID 17105798, PMID 18046048, PMID 18430965, PMID 21474786, PMID 24012740, PMID 24326421, PMID 29248236, PMID 32203306, PMID 32624280, PMID 33383350, PMID 33617303, PMID 39722695, PMID 41724634
I01RX001449 (1), K23HD045386 (1), P30CA015704 (1), R01CA184012 (1), R01DK049296 (1), U54HD042454 (1)